JP Morgan Chase
AVIR icon

JP Morgan Chase’s Atea Pharmaceuticals AVIR Stock Holding History

JP Morgan Chase’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Buy
945,918
+5,761
+0.6% +$28.7K ﹤0.01% 3574
2026
Q1 		$4.78M Sell
940,157
-408,137
-30% -$1.87M ﹤0.01% 3350
2025
Q4 		$4.81M Buy
1,348,294
+731,443
+119% +$2.32M ﹤0.01% 3341
2025
Q3 		$1.79M Sell
616,851
-35,810
-5% -$122K ﹤0.01% 4166
2025
Q2 		$2.35M Sell
652,661
-120,556
-16% -$360K ﹤0.01% 3788
2025
Q1 		$2.31M Buy
773,217
+363,958
+89% +$1.14M ﹤0.01% 3769
2024
Q4 		$1.37M Buy
409,259
+314,015
+330% +$1.04M ﹤0.01% 4402
2024
Q3 		$319K Buy
95,244
+49,028
+106% +$178K ﹤0.01% 5172
2024
Q2 		$153K Sell
46,216
-57,040
-55% -$213K ﹤0.01% 5294
2024
Q1 		$417K Buy
103,256
+34,830
+51% +$136K ﹤0.01% 4910
2023
Q4 		$209K Buy
68,426
+29
+0% +$88 ﹤0.01% 5368
2023
Q3 		$205K Buy
68,397
+5,500
+9% +$18.7K ﹤0.01% 5057
2023
Q2 		$235K Buy
62,897
+684
+1% +$2.56K ﹤0.01% 4980
2023
Q1 		$208K Sell
62,213
-147,805
-70% -$600K ﹤0.01% 5043
2022
Q4 		$1.01M Buy
210,018
+24,974
+13% +$126K ﹤0.01% 4031
2022
Q3 		$1.05M Buy
185,044
+140,439
+315% +$1.07M ﹤0.01% 3951
2022
Q2 		$317K Sell
44,605
-174,995
-80% -$1.19M ﹤0.01% 4822
2022
Q1 		$1.59M Buy
219,600
+173,680
+378% +$1.18M ﹤0.01% 3936
2021
Q4 		$411K Buy
45,920
+2,070
+5% +$32.3K ﹤0.01% 4952
2021
Q3 		$1.54M Buy
43,850
+16,143
+58% +$448K ﹤0.01% 3979
2021
Q2 		$596K Buy
27,707
+19,509
+238% +$586K ﹤0.01% 4590
2021
Q1 		$506K Sell
8,198
-30,928
-79% -$2.09M ﹤0.01% 4667
2020
Q4 		$1.63M Buy
+39,126
New +$1.26M ﹤0.01% 3624

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's AVIR Position: Q2 2026 in Review

JP Morgan Chase increased its Atea Pharmaceuticals (AVIR) stake by 0.61% in Q2 2026, buying an estimated $28.7K and bringing the position to 945,918 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3574.

JP Morgan Chase first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $4.81M in Q4 2025. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • JP Morgan Chase held 945,918 shares of Atea Pharmaceuticals worth $4.36M as of Q2 2026.
  • JP Morgan Chase bought 5,761 Atea Pharmaceuticals shares in Q2 2026, an estimated $28.7K.
  • Atea Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3574 holding.
  • JP Morgan Chase first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Atea Pharmaceuticals position peaked at $4.81M in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.